content: SECURITIES AND EXCHANGE COMMISSION
  
                               Washington, D.C. 20549
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
  Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
  
  Date of Report (Date of earliest event reported)              September 27, 1996
  
                                     ENZON, INC.
  
               (Exact name of registrant as specified in its charter)
               ------------------------------------------------------
  
  
  
         Delaware                    0-12957              22-237286
         --------                    -------              ---------
  
    (State or other jurisdiction   (Commission          (IRS Employer
         of incorporation)         File Number)          Identification)
  
  
  
          20 Kingsbridge Road,  Piscataway, New Jersey    08854
          (Address of principal executive offices)       (Zip Code)
  
  
  
  Registrant's telephone number, including area code               (908) 980-4500
  
  
  
  
            (Former name or former address, if changed since last report)
  
  
  
  
  
  
  
  
  
  <PAGE>
  
  
  
  Item 5.  Other Events
  -------  ------------
  
                    Enzon, Inc.  ("Enzon" or the "Company")  announced that it has
  selected  Medac GmbH (MEDAC) as its  marketing  partner in Europe and Russia for
  ONCASPAR (Registered Trademark).  ONCASPAR is Enzon's oncology product now being
  sold in the U.S. for the  indication of acute  lymphoblastic  leukemia (ALL) for
  patients  who  are  hypersensitive  to  native  forms  of  asparaginase.  MEDAC,
  headquartered   in  Hamburg,   Germany,   develops  and  markets  anti-  cancer,
  anti-coagulant and diagnostic products.  MEDAC will buy ONCASPAR from Enzon at a
  set price which  increases  over the term of the  agreement.  The agreement also
  contains escalating minimum annual purchase  requirements.  Additionally,  MEDAC
  will be  responsible  to obtain  registrations  for  ONCASPAR  in the  remaining
  European  countries  where it is not yet approved,  market the product in Europe
  and  Russia,  and  conduct  clinical  trials  in Europe  for front  line use and
  additional  indications  including  non-Hodgkin's  lymphoma,  adult ALL, chronic
  lymphocytic  leukemia  (CLL) and AIDS related  lymphoma.  MEDAC has an extensive
  sales base in Germany where ONCASPAR is already  approved,  as well as marketing
  capabilities throughout the rest of Europe and Russia. In particular,  MEDAC has
  extensive  sales   experience  with  the  leukemia  market  in  Europe.   Native
  asparaginase  is currently  sold in Europe as a treatment for not only pediatric
  ALL, but also for adult ALL, non-Hodgkin's lymphoma and other indications.
  
  
                                        - 2 -
  
  <PAGE>
  
  
  
           Enzon also announced that it has successfully completed the transfer of
  know-how  for  the   manufacture   of  PEG-INTRON  A  to  Schering   Corporation
  ("Schering"),  a subsidiary of Schering-Plough  Corporation,  and has received a
  payment of $1  million.  In 1995,  Schering  and Enzon  amended  their  existing
  agreement to include the transfer of Enzon's PEG-INTRON A know-how and worldwide
  manufacturing  rights to Schering  for $3 million,  of which $2 million was paid
  last year. At that time,  Schering  invested $2 million in Enzon's common stock.
  Enzon retained the option to be Schering's exclusive manufacturer of the product
  for the U.S. market.
  
  
  
  
                                        - 3 -
  
  <PAGE>
  
  
                                     SIGNATURES
                                     ----------
  
  
           Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
  the  Registrant  has duly  caused  this report to be signed on its behalf by the
  undersigned hereunto duly authorized.
  
  
  
  
  Dated:  November 4, 1996
  
  
  
                                                              ENZON, INC.
                                                              -----------
                                                             (Registrant)
  
                                               By:       /s/ KENNETH J. ZUERBLIS
                                                         Kenneth J. Zuerblis
                                                         Vice President, Finance
                                                         and Chief Financial
                                                         Officer
  
  
                                        - 4 -
metadata_documents: [{"type": "8-K", "sequence": "1", "description": "CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D)", "secsgml_size_bytes": 4427}]
metadata_filer: {"company-data": {"conformed-name": "ENZON INC", "cik": "0000727510", "assigned-sic": "2836", "irs-number": "222372868", "state-of-incorporation": "DE", "fiscal-year-end": "0630"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-12957", "film-number": "96653831"}, "business-address": {"street1": "20 KINGSBRIDGE RD", "city": "PISCATAWAY", "state": "NJ", "zip": "08854", "phone": "9089804500"}, "mail-address": {"street1": "C/O ROSS & HARDIES", "street2": "65 EAST 55TH STREET", "city": "NEW YORK", "state": "NY", "zip": "10022-3219"}}
text: SECURITIES AND EXCHANGE COMMISSION
  
                               Washington, D.C. 20549
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
  Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
  
  Date of Report (Date of earliest event reported)              September 27, 1996
  
                                     ENZON, INC.
  
               (Exact name of registrant as specified in its charter)
               ------------------------------------------------------
  
         Delaware                    0-12957              22-237286
         --------                    -------              ---------
  
    (State or other jurisdiction   (Commission          (IRS Employer
         of incorporation)         File Number)          Identification)
  
          20 Kingsbridge Road,  Piscataway, New Jersey    08854
          (Address of principal executive offices)       (Zip Code)
  
  Registrant's telephone number, including area code               (908) 980-4500
  
            (Former name or former address, if changed since last report)
  Item 5.  Other Events
  -------  ------------
  
                    Enzon, Inc.  ("Enzon" or the "Company")  announced that it has
  selected  Medac GmbH (MEDAC) as its  marketing  partner in Europe and Russia for
  ONCASPAR (Registered Trademark).  ONCASPAR is Enzon's oncology product now being
  sold in the U.S. for the  indication of acute  lymphoblastic  leukemia (ALL) for
  patients  who  are  hypersensitive  to  native  forms  of  asparaginase.  MEDAC,
  headquartered   in  Hamburg,   Germany,   develops  and  markets  anti-  cancer,
  anti-coagulant and diagnostic products.  MEDAC will buy ONCASPAR from Enzon at a
  set price which  increases  over the term of the  agreement.  The agreement also
  contains escalating minimum annual purchase  requirements.  Additionally,  MEDAC
  will be  responsible  to obtain  registrations  for  ONCASPAR  in the  remaining
  European  countries  where it is not yet approved,  market the product in Europe
  and  Russia,  and  conduct  clinical  trials  in Europe  for front  line use and
  additional  indications  including  non-Hodgkin's  lymphoma,  adult ALL, chronic
  lymphocytic  leukemia  (CLL) and AIDS related  lymphoma.  MEDAC has an extensive
  sales base in Germany where ONCASPAR is already  approved,  as well as marketing
  capabilities throughout the rest of Europe and Russia. In particular,  MEDAC has
  extensive  sales   experience  with  the  leukemia  market  in  Europe.   Native
  asparaginase  is currently  sold in Europe as a treatment for not only pediatric
  ALL, but also for adult ALL, non-Hodgkin's lymphoma and other indications.
  
                                        - 2 -
  Enzon also announced that it has successfully completed the transfer of
  know-how  for  the   manufacture   of  PEG-INTRON  A  to  Schering   Corporation
  ("Schering"),  a subsidiary of Schering-Plough  Corporation,  and has received a
  payment of $1  million.  In 1995,  Schering  and Enzon  amended  their  existing
  agreement to include the transfer of Enzon's PEG-INTRON A know-how and worldwide
  manufacturing  rights to Schering  for $3 million,  of which $2 million was paid
  last year. At that time,  Schering  invested $2 million in Enzon's common stock.
  Enzon retained the option to be Schering's exclusive manufacturer of the product
  for the U.S. market.
  
                                        - 3 -
  SIGNATURES
                                     ----------
  
           Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
  the  Registrant  has duly  caused  this report to be signed on its behalf by the
  undersigned hereunto duly authorized.
  
  Dated:  November 4, 1996
  
                                                              ENZON, INC.
                                                              -----------
                                                             (Registrant)
  
                                               By:       /s/ KENNETH J. ZUERBLIS
                                                         Kenneth J. Zuerblis
                                                         Vice President, Finance
                                                         and Chief Financial
                                                         Officer
  
                                        - 4 -